OpenEvidence, which has been called “ChatGPT for doctors,” is raising $250 million in equity financing at a $12 billion valuation, The Information reported.
The three-year-old company, which secured $200 million in October to be valued at $6 billion, generates annual recurring revenue of $150 million, according to the Dec. 12 story.
The startup also landed a $75 million series A funding round in early 2025 and partnered with the American College of Cardiology in November to accelerate the translation of research into clinical practice. Becker’s reached out to OpenEvidence for comment on the report.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
